Welcome to our dedicated page for Bullfrog AI Holdings news (Ticker: BFRGW), a resource for investors and traders seeking the latest updates and insights on Bullfrog AI Holdings stock.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) generates news at the intersection of artificial intelligence, bioinformatics, and pharmaceutical development. This page aggregates coverage related to the company’s AI-driven platforms for drug discovery and clinical trial optimization, giving readers a focused view of how its technology is being applied and discussed across the life sciences sector.
Company announcements highlight the use of its proprietary bfLEAP ae analytics engine, bfPREP ae data preparation module, and BullFrog Data Networks ae platform in real-world settings. Recent news includes precision-oncology analyses in pancreatic adenocarcinoma, where BullFrog AI reports identifying patient subgroups with an almost threefold increase in mean survival in glufosfamide trial data, as well as an accepted abstract and poster presentation at the ASCO Gastrointestinal Cancers Symposium.
Investors and industry observers can also follow updates on commercial collaborations, such as the company’s work with Eleison Pharmaceuticals on late-stage oncology data and its partnership with Sygnature Discovery to introduce BullFrog Data Networks ae to global biopharma clients. Additional news items cover technical conference presentations, whitepapers on AI in bioinformatics, and webinars that detail how BullFrog AI operationalizes human-in-the-loop AI agents in clinical data workflows.
By reviewing the news feed for BFRG and BFRGW, readers can track developments in BullFrog AI’s scientific validation efforts, commercial initiatives, and regulatory disclosures. This page provides a centralized view of press releases and related articles for those monitoring the company’s role in AI-enabled drug development.
BullFrog AI Holdings (NASDAQ: BFRG) announced new research supporting the potential of its drug candidate BF-114 in treating liver diseases. The study, published in Cell Reports and led by Dr. Lopa Mishra, provides evidence for the role of β2-spectrin in obesity, MASLD, MASH, and HCC. Key points:
- BF-114 targets β2-spectrin and may prevent liver disease progression
- Research strengthens the scientific foundation for BF-114
- BullFrog AI plans to use its AI platform to analyze single-cell data for further insights
- Dr. Mishra joins BullFrog AI's Scientific Advisory Board
The company aims to leverage these findings to advance BF-114's development and explore additional therapeutic applications.
BullFrog AI Holdings (NASDAQ: BFRG; BFRGW), a leader in AI-driven drug discovery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company's CEO, Vin Singh, will deliver a presentation that will be available on demand starting September 9, 2024, at 7:00am ET. Interested parties can access live and archived webcasts of the event through BullFrog AI's investor relations website at investors.bullfrogai.com. This participation provides an opportunity for the company to showcase its advancements in AI-driven drug discovery to a global investment audience.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has announced significant progress in its collaboration with the Lieber Institute for Brain Development (LIBD) to uncover new insights into bipolar disorder (BD) pathways and potential drug targets. The research has identified specific molecular pathways associated with BD, enabling the discovery of new candidate drug targets.
Key findings include:
- Significant enrichment in 6 out of 68 clusters from the LIBD brain dataset
- Two substantially enriched clusters in the Dentate Gyrus
- One specific cluster associated with BD in the Dorsolateral Prefrontal Cortex
- Potential dysregulation of pro-inflammatory pathways
- Identification of novel pathways significant to BD pathophysiology
BullFrog AI is now focusing on validating these findings in wet lab settings and engaging with pharmaceutical partners to advance these discoveries.
BullFrog AI (NASDAQ: BFRG) is hosting a live investor webinar on June 12, 2024, at 4:15 p.m. ET, featuring insights from CSO Tom Chittenden and LIBD CEO Daniel Weinberger on their collaborative research. The study, using over 2,800 brain samples, has revealed novel insights into psychiatric conditions such as schizophrenia and bipolar disorder through advanced AI techniques. This collaboration has enabled clustering based on biological data, uncovering potential biomarkers and drug targets. The event aims to provide comprehensive details on these findings and discuss future revenue opportunities through potential pharmaceutical partnerships.
BullFrog AI and the Lieber Institute for Brain Development (LIBD) announced significant progress in their collaboration to identify novel drug targets for neuropsychiatric disorders. Using AI and machine learning, they have discovered patient subgroups within conditions like major depression, schizophrenia, and bipolar disorder. This approach led to identifying key genes that present new potential drug targets. BullFrog AI is applying Causal AI to validate these targets, aiming to develop targeted treatments for psychiatric disorders. The collaboration has also started engagements with pharmaceutical companies for strategic partnerships.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Bullfrog AI Holdings (BFRGW)?
